Oral Mucosal Injury in Oncology Patients

Abstract

The field of oral mucosal injury caused by cancer therapies has strategically matured in the scientific as well as clinical realms over the past decade. Prior to the late 1990s, the condition had been viewed by many healthcare providers as an inevitable consequence of high-dose chemotherapy and other intensive therapies in oncology practice. Fortunately, expanding insights into the pathobiology as well as design strategies for clinical trials in recent years have fostered development of high-quality clinical practice guidelines as well as health professional education relative to prevention and treatment. This report is directed to analysis of this contemporary modeling. Guideline-based management recommendations that have emerged over the past year and controversies in the field are highlighted.